actemra concentrat pentru solutie perfuzabila 20 mg/ml
roche registration ltd - tocilizumabum - concentrat pentru solutie perfuzabila - 20 mg/ml
actemra concentrat pentru solutie perfuzabila 20 mg/ml
roche registration ltd - tocilizumabum - concentrat pentru solutie perfuzabila - 20 mg/ml
taltz
eli lilly and company (ireland) limited - ixekizumab - psoriazis - imunosupresoare - placa psoriasistaltz este indicat pentru tratamentul formelor moderate până la severe de psoriazis în plăci la adulți care sunt candidați pentru terapia sistemică. psoriazică arthritistaltz, singur sau în asociere cu metotrexatul, este indicat pentru tratamentul artritei psoriazice active la pacienții adulți care au răspuns inadecvat sau care au intoleranță la unul sau mai multe boli medicamentele anti-reumatice droguri (dmard) terapii.
tremfya
janssen-cilag international nv - guselkumab - psoriazis - imunosupresoare - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.
ilumetri
almirall s.a - tildrakizumab - psoriazis - imunosupresoare, inhibitori de interleukină, - ilumetri este indicat pentru tratamentul adulților cu forme moderate sau severe de psoriazis în plăci la care sunt candidați pentru terapia sistemică.
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresoare - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
bimzelx
ucb pharma s.a. - bimekizumab - psoriazis - imunosupresoare - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
omvoh
eli lilly nederland b.v. - mirikizumab - colită, ulcerativă - imunosupresoare - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
actemra concentrat pentru solutie perfuzabila 20 mg/ml
roche registration ltd - concentrat pentru solutie perfuzabila - 20 mg/ml
cosentyx
novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresoare - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriazică arthritiscosentyx, singur sau în asociere cu metotrexat (mtx), este indicat pentru tratamentul artritei psoriazice active la pacienții adulți, atunci când răspunsul la precedenta modificare a bolii anti-reumatice droguri (marmb) a fost terapia inadecvată. spondilartrită axială (axspa)spondilita anchilozantă (ca, radiografic spondilartrită axială)cosentyx este indicat pentru tratamentul de spondilită anchilozantă activă la adulți care au răspuns inadecvat la terapia convențională. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.